Title:DDX59-AS1: A Novel Prognostic Biomarker and Immunotherapy Predictor in Lung Adenocarcinoma
Volume: 33
Issue: 8
Author(s): Yanli Wang, Wei Li, Su Wei, Lixi Zhang, Dongbing Li and Xu Qi*
Affiliation:
- Department of Respiratory and Critical Medicine, First Affiliated Hospital with Nanjing Medical University,
Nanjing, 210029, Jiangsu, China
Keywords:
DDX59-AS1, lung adenocarcinoma, biomarker, prognosis, immune infiltration, cytosolic DNA sensing pathway.
Abstract:
Background: The precise function of DDX59 Antisense RNA 1 (DDX59-
AS1) in lung adenocarcinoma (LUAD) has yet to be fully elucidated.
Objective: This study uses bioinformatics analysis and experimental validation to investigate
the association between DDX59-AS1 and LUAD.
Methods: This study uses statistical analysis and database interrogation to investigate
the potential association between DDX59-AS1 expression and various clinical characteristics,
prognostic factors, regulatory networks, and immune infiltration in LUAD. The
quantification of DDX59-AS1 expression in LUAD cell lines is conducted through the
use of quantitative real-time polymerase chain reaction (qRT-PCR).
Results: DDX59-AS1 showed significantly elevated levels of expression in patients
with LUAD. High levels of DDX59-AS1 expression were found to be significantly associated
with poorer overall survival (OS) in patients with LUAD (p = 0.024). Furthermore,
an independent correlation was observed between high DDX59-AS1 expression
(p = 0.037) and OS in LUAD patients. DDX59-AS1 was found to be involved in various
pathways, including glutathione metabolism, proteasome function, and the cytosolic
DNA sensing pathway, among others. A significant correlation was observed between
the expression levels of DDX59-AS1 and immune cell infiltration in the context of LUAD.
Notably, elevated expression of DDX59-AS1 was observed in LUAD cell lines
compared to the non-cancerous Beas-2B cell line.
Conclusion: A significant correlation was observed between elevated DDX59-AS1 expression
in patients with LUAD and adverse prognosis, alongside increased immune infiltration.
These results indicate that DDX59-AS1 may function as a prognostic marker
for LUAD and a potential predictor of immunotherapy response.
